Western Blot: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Total protein from HL-60, HepG2, HCT-116 and human placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk ...read more
Immunocytochemistry/ Immunofluorescence: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The ...read more
Biological Strategies: Immunohistochemistry: TRAILR2/TNFRSF10B Antibody [NB100-56618] - Pharmacodynamic assays for ONC201. IHC analyses of CHOP, TRAILR2/TNFRSF10B, and double-stranded DNA breaks (TUNEL) in ...read more
Western Blot: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis using the Azide Free version of NB100-56618. Detection of 20 ug of whole cell lysates from HL60 cells with anti-TRAIL-R2 at 5 ug/ml.
Immunohistochemistry-Paraffin: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis of a formalin fixed paraffin-embedded (FFPE) human brain cerebellum using 1:200 conc. of TRAIL R2/TNFRSF10B antibody on a Bond Rx ...read more
Rabbit anti-DR5 polyclonal antibody was raised against a peptide corresponding to amino acids 388 to 407 (isoform 2) of human DR5 precursor (1,2). The same sequence is found in isoform 1 at amino acids 417-436.
Protein G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Flow Cytometry (Cell Surface): As reported in KOYAMA (2003) ICC/IF: As reported in Georgakis et al. (2005) IHC-P As reported in Younes et al. (2006). Use in IHC reported in scientific literature (PMID 27740879). Use in Flow-cell surface reported in scientific literature (PMID: 16426839).
Mouse reactivity reported in scientific literature (PMID: 21474767).
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.05% Sodium Azide
Protein G purified
Alternate Names for TRAILR2/TNFRSF10B Antibody
death domain containing receptor for TRAIL/Apo-2L
Death receptor 5
KILLERapoptosis inducing protein TRICK2A/2B
TNF-related apoptosis-inducing ligand receptor 2
TRAIL receptor 2
TRAIL-R2apoptosis inducing receptor TRAIL-R2
TRAILR2cytotoxic TRAIL receptor-2
tumor necrosis factor receptor superfamily member 10B
tumor necrosis factor receptor superfamily, member 10b
tumor necrosis factor receptor-like protein ZTNFR9
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently (1-2). Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-kB.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Total cell lysates from T47D and MDA-MB-231 cells were subjected to western blot. PVDF membrane were probed with 2.5 mm/ml Human TRAIL R2 (NB100-56618). A specific band was detected for TRAIL R2 at approximately 48~50 kDa. This experiment was conducted under reducing conditions
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.